A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01683279 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 11, 2012
Last Update Posted : February 16, 2022
|
Sponsor:
Seattle Children's Hospital
Information provided by (Responsible Party):
Rebecca Gardner, Seattle Children's Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | January 7, 2015 |
| Estimated Study Completion Date : | January 7, 2030 |